Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Personal Genome Diagnostics (PGD)

Request full access

Empowering the fight against cancer by unlocking actionable information from the genome

Baltimore, United StatesFounded 2010Biotech & Life Sciences

About Personal Genome Diagnostics (PGD)

Personal Genome Diagnostics (PGD), now a subsidiary of Labcorp, operates at the forefront of precision oncology, developing and commercializing a portfolio of genomic testing products for cancer. The company was founded in 2010 as a spin-out from Johns Hopkins University by Dr. Luis Diaz and Dr. Victor Velculescu, internationally recognized pioneers in cancer genomics who performed the first genome-wide sequence analyses in human cancers. Their research in next-generation sequencing (NGS) and the development of non-invasive "liquid biopsy" techniques formed the company's scientific foundation.

PGD's business model centers on providing both services and kitted in-vitro diagnostic (IVD) products to clinical laboratories, health systems, and biopharmaceutical companies. This strategy aims to decentralize cancer genomic profiling, allowing tests to be performed locally and results delivered more quickly, rather than relying on a centralized lab. Revenue is generated through the sale of these regulated diagnostic kits and by offering genomic analysis services to support pharmaceutical and biotechnology partners in clinical trials and companion diagnostic development.

The company's flagship offering is the PGDx elio™ portfolio, which includes both tissue-based and liquid biopsy tests. The PGDx elio™ tissue complete product, which received FDA clearance in April 2020, is a comprehensive genomic profiling kit that analyzes over 500 genes from tumor tissue to identify various genetic alterations, microsatellite instability (MSI), and tumor mutation burden (TMB). This was the first diagnostic kit of its kind cleared for use by any laboratory in the country, a significant milestone that facilitates broader access to precision oncology. The portfolio also includes liquid biopsy tests, such as PGDx elio™ plasma complete, which analyze circulating tumor DNA from a blood sample, offering a non-invasive method for genomic profiling.

The company's journey has been marked by substantial financial and strategic milestones, including a $21.4 million Series A in 2015, a $75 million Series B in 2018 co-led by Bristol-Myers Squibb, and a $103 million Series C in 2021. These funding rounds supported product development, global commercialization, and expansion of partnerships. In December 2021, Labcorp announced its acquisition of PGDx for $450 million, with up to an additional $125 million in milestone payments, a deal that was finalized in February 2022. This acquisition integrates PGDx's decentralized testing platforms with Labcorp's extensive diagnostic and drug development capabilities.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2010
Headquarters
Baltimore, United States
Employees
65
Open positions
None listed
Dealroom signal
64.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Testing, Biotechnology, Oncology, DNA, Genetics and genomics, Spinout, Genome Engineering, Tech for Biotech and Pharma, Biotech and Pharma, medical testing, DT and LS
Business model
Manufacturing

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Dec 2021 $575M $575M LabCorp ↗
SERIES COther financing Feb 2021 $103M $412M Windham Venture Partners · PFM Health Sciences · Innovatus Capital Partners · Vensana Capital —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Personal Genome Diagnostics (PGD) website traffic

Latest recorded traffic for Personal Genome Diagnostics (PGD) is 1.8K monthly website visits, up 38.5% over the last three months. Personal Genome Diagnostics (PGD)'s team declined 13.3% over the past year.

Latest monthly visits1.8K 3-month web change+38.5% 1-year team growth-13.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Personal Genome Diagnostics (PGD) in the Baltimore ecosystem

Live from Dealroom

The Personal Genome Diagnostics (PGD) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • NEA
  • Windham Venture Partners
  • 3B Future Health Fund
  • Bristol-Myers Squibb
  • Maryland Venture Fund

Series B and later9 investors entered at this stage

  • Innovatus Capital Partners
  • PFM Health Sciences
  • Vensana Capital
  • Catalio Capital Management
  • Sands Capital Management
  • Rock Springs Capital
  • Northpond Ventures
  • Cowen Healthcare Investments
  • Kern Capital

Other known investors2 additional known investors

  • Johns Hopkins University
  • LabCorp
Team profiled 27 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Personal Genome Diagnostics (PGD) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Personal Genome Diagnostics (PGD)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.